Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD).

Sanofi has acquired rights to co-develop and co-market Teva’s TEV-48574, currently in phase 2b testing for both ulcerative colitis and Crohn’s disease, with results expected next year.

JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine ...

The Business Research Company The Business Research Company's Effective Pain Management Solutions Global Market Report 2025 – Market Size, ...

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and ...

The Business Research Company The Business Research Company's Estrogen Receptor Modulators Global Market Report 2025 – Market Size, Trends, ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.

The Business Research Company's Eye-Drop And Lubricants Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Save 30% on all global market reports with code ONLINE30 - stay ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

The global vaginal and vulval inflammatory diseases treatment market is estimated to grow from USD 3,313.3 million in 2025 to USD 5,500.7 million by 2035, recording a CAGR of 5.2% during the forecast ...